351 related articles for article (PubMed ID: 27316683)
1. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
Overdijk MB; Jansen JH; Nederend M; Lammerts van Bueren JJ; Groen RW; Parren PW; Leusen JH; Boross P
J Immunol; 2016 Aug; 197(3):807-13. PubMed ID: 27316683
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
6. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
7. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
[TBL] [Abstract][Full Text] [Related]
13. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W; Yu J; Sun K; Song Q; Li Y; He Y; Wang Y; Xu G; Wang C; Chen B
Front Immunol; 2024; 15():1410457. PubMed ID: 38765013
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
Yu T; Qiao C; Lv M; Tang L
BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
[TBL] [Abstract][Full Text] [Related]
16. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
18. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
20. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
